In addition, HDAC6-specific inhibitors also used in neurodegenerative disease, the absence of a novel CHIP substrate, HDAC6, has been shown to mitigate the abnormal accumulation of Tau, while the absence of HDAC6 activity further enhances the efficacy of Hsp90 inhibitors, leading to tau degradation. This evidence concerns the gene MAPT and neurodegenerative disease.